Efficacy and safety of an inactivated virus-particle vaccine for SARS-CoV-2, BIV1-CovIran: randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial

OBJECTIVE: To report the efficacy, safety, and exploratory immunogenicity findings of two 5 µg doses of the BIV1-CovIran vaccine. DESIGN: Randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial. SETTING: In six cities of Iran, including Bushehr, Isfahan, Karaj, Mashhad, Shi...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohraz, Minoo, Vahdat, Katayoun, Ghamari, Seyyed-Hadi, Abbasi-Kangevari, Mohsen, Ghasemi, Erfan, Ghabdian, Yasaman, Rezaei, Negar, Pouya, Maryam Amini, Abdoli, Asghar, Malekpour, Mohammad-Reza, Koohgir, Keyvan, Saeedi Moghaddam, Sahar, Tabarsi, Payam, Moghadami, Mohsen, Khorvash, Farzin, Khodashahi, Rozita, Salehi, Mohammadreza, Hosseini, Hamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520577/
https://www.ncbi.nlm.nih.gov/pubmed/37734752
http://dx.doi.org/10.1136/bmj-2023-070464

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520577/
https://www.ncbi.nlm.nih.gov/pubmed/37734752
http://dx.doi.org/10.1136/bmj-2023-070464

Ejemplares similares